Measurable urinary albumin predicts cardiovascular risk among normoalbuminuric patients with type 2 diabetes

Journal of the American Society of Nephrology

Volumn 23, Issue 10, 2012, Pages 1717-1724

  Ruggenenti, Piero ^a,b   Porrini, Esteban ^a   Motterlini, Nicola ^a   Perna, Annalisa ^a   Ilieva, Aneliya Parvanova ^a   Iliev, Ilian Petrov ^a   Dodesini, Alessandro Roberto ^b   Trevisan, Roberto ^b   Bossi, Antonio ^c   Sampietro, Giuseppe ^d   Capitoni, Enrica ^b   Gaspari, Flavio ^a   Rubis, Nadia ^a   Ene Iordache, Bogdan ^a   Remuzzi, Giuseppe ^a,b  

^a MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^b OSPEDALI RIUNITI   (Italy)

^c TREVIGLIO HOSPITAL   (Italy)

^d Epidemiological Observatory   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALBUMIN; ANTIDIABETIC AGENT; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PLACEBO; TRANDOLAPRIL; VERAPAMIL;

ADULT; AGED; ALBUMINURIA; ANTIHYPERTENSIVE THERAPY; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CAROTID ARTERY DISEASE; CEREBROVASCULAR ACCIDENT; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DIABETIC PATIENT; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE ASSOCIATION; DRUG EFFICACY; FEMALE; HAZARD RATIO; HEART FAILURE; HEART INFARCTION SIZE; HOSPITALIZATION; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MICROALBUMINURIA; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PREDICTIVE VALUE; PREVALENCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; SENSITIVITY AND SPECIFICITY; TREATMENT DURATION; URINALYSIS; URINARY EXCRETION;

EID: 84867164882     PISSN: 10466673     EISSN: 15333450     Source Type: Journal    
DOI: 10.1681/ASN.2012030252     Document Type: Article

References (26)

1. Adler AI, Stevens RJ, Manley SE, Bilous RW, Cull CA, Holman RR; UKPDS GROUP: Development and progression of nephropathy in type 2 diabetes: The United Kingdom Prospective Diabetes Study (UKPDS 64). Kidney Int 63: 225-232, 2003 (Pubitemid 35463925)
2. Dinneen SF, Gerstein HC: The association of microalbuminuria and mortality in non-insulin-dependent diabetes mellitus. A systematic overview of the literature. Arch Intern Med 157: 1413-1418, 1997 (Pubitemid 27300386)
3. Nelson RG, Pettitt DJ, Carraher MJ, Baird HR, Knowler WC: Effect of proteinuria on mortality in NIDDM. Diabetes 37: 1499-1504, 1988
4. Rayner M, Petersen S, Buckley C, Press V: Coronary heart disease statistics: Diabetes supplement. 2001 edition. Available at: http://www.bhf.org.uk/publications/view-publication.aspx?ps=1001401. Accessed on August 8, 2012
5. Mattock MB, Barnes DJ, Viberti G, Keen H, Burt D, Hughes JM, Fitzgerald AP, Sandhu B, Jackson PG: Microalbuminuria and coronary heart disease in NIDDM: An incidence study. Diabetes 47: 1786-1792, 1998 (Pubitemid 28476254)
6. Borch-Johnsen K, Feldt-Rasmussen B, Strandgaard S, Schroll M, Jensen JS: Urinary albumin excretion. An independent predictor of ischemic heart disease. Arterioscler Thromb Vasc Biol 19: 1992-1997, 1999 (Pubitemid 29379934)
7. Hillege HL, Fidler V, Diercks GF, van Gilst WH, de Zeeuw D, van Veldhuisen DJ, Gans RO, Janssen WM, Grobbee DE, de Jong PE; Prevention of Renal and Vascular End Stage Disease (PREVEND) Study Group: Urinary albumin excretion predicts cardiovascular and non-cardiovascular mortality in general population. Circulation 106: 1777-1782, 2002
8. Ruggenenti P, Remuzzi G: Time to abandon microalbuminuria? Kidney Int 70: 1214-1222, 2006 (Pubitemid 44435172)
9. Ruggenenti P, Fassi A, Ilieva AP, Bruno S, Iliev IP, Brusegan V, Rubis N, Gherardi G, Arnoldi F, Ganeva M, Ene-Iordache B, Gaspari F, Perna A, Bossi A, Trevisan R, Dodesini AR, Remuzzi G; Bergamo Nephrologic Diabetes Complications Trial (BENEDICT) Investigators: Preventing microalbuminuria in type 2 diabetes. N Engl J Med 351: 1941-1951, 2004
10. Ruggenenti P, Perna A, Ganeva M, Ene-Iordache B, Remuzzi G; BENEDICT Study Group: Impact of blood pressure control and angiotensin-converting enzyme inhibitor therapy on new-onset microalbuminuria in type 2 diabetes: A post hoc analysis of the BENEDICT trial. J Am Soc Nephrol 17: 3472-3481, 2006 (Pubitemid 44865289)
11. De Cosmo S, Motterlini N, Prudente S, Pellegrini F, Trevisan R, Bossi A, Remuzzi G, Trischitta V, Ruggenenti P; BENEDICT Study Group: Impact of the PPAR-gamma2 Pro12Ala polymorphism and ACE inhibitor therapy on new-onset microalbuminuria in type 2 diabetes: evidence from BENEDICT. Diabetes 58: 2920-2929, 2009
12. Writing Team for the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group: Sustained effect of intensive treatment of type 1 diabetes mellitus on development and progression of diabetic nephropathy: the Epidemiology of Diabetes Interventions and Complications (EDIC) study. JAMA 290: 2159-2167, 2003
13. Bosch J, Lonn E, Pogue J, Arnold JM, Dagenais GR, Yusuf S; HOPE/HOPE-TOO Study Investigators: Long-term effects of ramipril on cardiovascular events and on diabetes: Results of the HOPE study extension. Circulation 112: 1339-1346, 2005 (Pubitemid 41266730)
14. Gerstein HC, Mann JF, Yi Q, Zinman B, Dinneen SF, Hoogwerf B, Hallé JP, Young J, Rashkow A, Joyce C, Nawaz S, Yusuf S; HOPE Study Investigators: Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals. JAMA 286: 421-426, 2001 (Pubitemid 32681484)
15. Wachtell K, Ibsen H, Olsen MH, Borch-Johnsen K, Lindholm LH, Mogensen CE, Dahlöf B, Devereux RB, Beevers G, de Faire U, Fyhrquist F, Julius S, Kjeldsen SE, Kristianson K, Lederballe-Pedersen O, Nieminen MS, Okin PM, Omvik P, Oparil S, Wedel H, Snapinn SM, Aurup P: Albuminuria and cardiovascular risk in hypertensive patients with left ventricular hypertrophy: The LIFE study. Ann Intern Med 139: 901-906, 2003
16. Arnlöv J, Evans JC, Meigs JB, Wang TJ, Fox CS, Levy D, Benjamin EJ, D'Agostino RB, Vasan RS: Low-grade albuminuria and incidence of cardiovascular disease events in nonhypertensive and nondiabetic individuals: The Framingham Heart Study. Circulation 112: 969-975, 2005 (Pubitemid 41170264)
17. Forman JP, Brenner BM: 'Hypertension' and 'microalbuminuria': The bell tolls for thee. Kidney Int 69: 22-28, 2006 (Pubitemid 43117734)
18. Pistrosch F, Herbrig K, Kindel B, Passauer J, Fischer S, Gross P: Rosiglitazone improves glomerular hyperfiltration, renal endothelial dysfunction, and microalbuminuria of incipient diabetic nephropathy in patients. Diabetes 54: 2206-2211, 2005 (Pubitemid 40911285)
19. Chagnac A, Weinstein T, Herman M, Hirsh J, Gafter U, Ori Y: The effects of weight loss on renal function in patients with severe obesity. J Am Soc Nephrol 14: 1480-1486, 2003 (Pubitemid 36687049)
20. UK Prospective Diabetes Study Group: Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 317: 703-713, 1998
21. Parving HH, Lehnert H, Bröchner-Mortensen J, Gomis R, Andersen S, Arner P; Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria Study Group: The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 345: 870-878, 2001
22. Brouwers FP, Asselbergs FW, Hillege HL, de Boer RA, Gansevoort RT, van Veldhuisen DJ, van Gilst WH: Long-term effects of fosinopril and pravastatin on cardiovascular events in subjects with microalbuminuria: Ten years of follow-up of Prevention of Renal and Vascular End-stage Disease Intervention Trial (PREVEND IT). Am Heart J 161: 1171-1178, 2011
23. Mancini GB, Henry GC, Macaya C, O'Neill BJ, Pucillo AL, Carere RG, Wargovich TJ, Mudra H, Lüscher TF, Klibaner MI, Haber HE, Uprichard AC, Pepine CJ, Pitt B: Angiotensin-converting enzyme inhibition with quinapril improves endothelial vasomotor dysfunction in patients with coronary artery disease. The TREND (Trial on Reversing ENdothelial Dysfunction) Study. Circulation 94: 258-265, 1996 (Pubitemid 26266107)
24. BENEDICT Group: The BErgamo NEphrologic DIabetes Complications Trial (BENEDICT): Design and baseline characteristics. Control Clin Trials 24: 442-461, 2003
25. Royston P, Altman DG, Sauerbrei W: Dichotomizing continuous predictors in multiple regression: A bad idea. Stat Med 25: 127-141, 2006 (Pubitemid 43136953)
26. Royston P, Sauerbrei W: Multivariable Model-Building. A Pragmatic Approach to Regression Analysis Based on Fractional Polynomials for Modelling Continuous Variables, West Sussex, United Kingdom, J Wiley, 2008.